Coya Therapeutics (COYA) Expected to Announce Quarterly Earnings on Tuesday

Coya Therapeutics (NASDAQ:COYA) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $1.9250 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 9:30 AM ET.

Coya Therapeutics Trading Down 4.6%

COYA stock opened at $4.53 on Monday. The stock’s 50 day simple moving average is $4.77 and its 200 day simple moving average is $5.59. Coya Therapeutics has a 12-month low of $3.94 and a 12-month high of $7.75. The stock has a market capitalization of $94.77 million, a PE ratio of -4.08 and a beta of 0.23.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd purchased a new position in shares of Coya Therapeutics in the 4th quarter worth $192,000. Occudo Quantitative Strategies LP bought a new position in Coya Therapeutics in the fourth quarter valued at about $66,000. Millennium Management LLC purchased a new position in Coya Therapeutics in the fourth quarter worth about $121,000. 683 Capital Management LLC purchased a new position in Coya Therapeutics in the fourth quarter worth about $465,000. Finally, Cetera Investment Advisers bought a new stake in shares of Coya Therapeutics during the 4th quarter valued at about $128,000. 39.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

COYA has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday, February 18th. Finally, Chardan Capital reissued a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, January 8th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.00.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.